Stuart S Thompson

US Patent:

8377636, Feb 19, 2013

Filed:

Apr 14, 2008

Appl. No.:

12/082762

Inventors:

John D. Haley - Sea Cliff NY, US
Stuart Thompson - Port Washington NY, US

Assignee:

OSI Pharmaceuticals, LLC - Farmingdale NY

International Classification:

G01N 33/53
G01N 33/574

US Classification:

435 4, 435 71, 435 723

Abstract:

The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Based on the surprising discovery that tumors cells after having undergone an EMT, while being mesenchymal-like, still express characteristics of both epithelial and mesenchymal cells, and that such cells have altered sensitivity to inhibition by receptor protein-tyrosine kinase inhibitors, in that they have become relatively insensitive to EGFR kinase inhibitors, but have frequently acquired sensitivity to inhibitors of other receptor protein-tyrosine kinases such as PDGFR or FGFR, methods have been devised for determining levels of specific epithelial and mesenchymal biomarkers that identify such “hybrid” tumor cells (e. g. determination of co-expression of vimentin and epithelial keratins), and thus predict the tumor's likely sensitivity to inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Improved methods for treating cancer patients with EGFR, PDGFR or FGFR kinase inhibitors that incorporate such methodology are also provided.